The case in front of me: semaglutide · twelve weeks · room temperature.
I want to decide this in advance so that I am not deciding it under pressure later.
Assume I will follow the plan I write down, so I would like it to be a good one.
What would you do, and what would make you change course?
The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
If testing multiple vials, state how many you tested and why you chose those vials.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsIt helps to be literal here: batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Stated carefully, if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
More usefully, a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
The underlying point is that testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 6 Nov 2025 by e_dziedzic — added the placebo-arm figures
The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
If testing multiple vials, state how many you tested and why you chose those vials.
The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.